Berenberg has upgraded AbbVie Inc (ABBV) to Buy from Hold, a decision made on September 16, 2025. The current share price stands at $235.48.
This upgrade underscores a more positive outlook on AbbVie’s prospects, suggesting enhanced fundamentals or increased confidence in the company’s strategic direction. AbbVie, headquartered in North Chicago, Illinois, is a research-based biopharmaceutical company employing 55,000 full-time staff. The firm focuses on the development and sale of pharmaceutical products across various sectors, including Immunology, Oncology, Aesthetics, and Neuroscience.
As of November 20, 2025, AbbVie boasts a market capitalisation of $411.6 billion and a P/E ratio of 172.38. The company’s earnings per share (EPS) stands at 1.35, with a dividend yield of 297.1%. Upcoming earnings are scheduled for July 29, 2026, with an EPS estimate of $3.71 and revenue projected at $17.0 billion.
Analyst ratings and price targets are informed by extensive research and financial modelling. While these assessments can offer valuable insights, they are based on assumptions that may not materialise as anticipated. Investment decisions should incorporate a range of factors, including company fundamentals, competitive positioning, and industry trends, rather than relying solely on analyst opinions. Analyst ratings are subject to change as new information emerges, and differing views may exist among analysts regarding the same company.